Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Riva-Clarithromycin (02346532). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
CLARITHROMYCIN
Form:
24 of 24 products shown
16 general benefit · 8 not a benefit
Other products in the same Health Canada class (J01FA) — coverage varies; not interchangeable
Azithromycin (Zithromax): general benefit, Limited Use 549, Not a benefit
Erythromycin base (Erythromid): general benefit, Not a benefit
Erythromycin estolate (Ilosone): general benefit, Not a benefit
Erythromycin ethylsuccinate (Ees-200): general benefit, Not a benefit
Biaxin · DIN 02146908 · 125mg/5mL · Ped Gran
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Biaxin (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Biaxin · DIN 02146908
Manufacturer: BGP Pharma ULC; listing date 1997-08-28
Daily cost (source): $3.5000
Health Canada: Marketed since 2016-04-08 · brand BIAXIN · ATC J01FA09 CLARITHROMYCIN · form Granules for suspension · route Oral · ingredients CLARITHROMYCIN 125 MG/5ML · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18066 · Verify on the e-Formulary ↗ (DIN 02146908)
Source record
DIN 02146908: Biaxin
Raw flags: sec3=Y
Item: 081212030; group id 21; item number 0033; lccId None; manufacturer id BGP
Source form: Ped Gran; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.3500; ministry $0.2388
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02146908
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18066Interchangeable products
Taro-Clarithromycin · DIN 02390442 · $0.2388
Shortage status: resolved shortage (ended 2025-03-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02146908
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Clarithromycin · DIN 02390442 · 125mg/5mL · Ped Gran
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Clarithromycin · DIN 02390442
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2013-01-29
Daily cost (source): $2.3880
Health Canada: Marketed since 2017-07-31 · brand TARO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Powder for suspension · route Oral · ingredients CLARITHROMYCIN 125 MG/5ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Clarithromycin: Formulary list price $0.2388/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2388 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87588 · Verify on the e-Formulary ↗ (DIN 02390442)
Source record
DIN 02390442: Taro-Clarithromycin
Raw flags: sec3=Y
Item: 081212030; group id 21; item number 0033; lccId None; manufacturer id TAR
Source form: Ped Gran; strength: 125mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.2388; ministry $0.2388
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390442
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87588Interchangeable products
Biaxin · DIN 02146908 · $0.2388
Shortage status: resolved shortage (ended 2025-09-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390442
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biaxin · DIN 02244641 · 250mg/5mL · suspension
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Biaxin (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Biaxin · DIN 02244641
Manufacturer: BGP Pharma ULC; listing date 2003-01-30
Daily cost (source): $6.8660
Health Canada: Marketed since 2016-04-26 · brand BIAXIN · ATC J01FA09 CLARITHROMYCIN · form Granules for suspension · route Oral · ingredients CLARITHROMYCIN 250 MG/5ML · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68628 · Verify on the e-Formulary ↗ (DIN 02244641)
Source record
DIN 02244641: Biaxin
Raw flags: sec3=Y
Item: 081212031; group id 21; item number 0034; lccId None; manufacturer id BGP
Source form: Susp; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.6866; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244641
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68628Interchangeable products
Taro-Clarithromycin · DIN 02390450 · $0.4685
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244641
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Taro-Clarithromycin · DIN 02390450 · 250mg/5mL · suspension
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Clarithromycin · DIN 02390450
Manufacturer: Taro Pharmaceuticals Inc.; listing date 2013-01-29
Daily cost (source): $4.6850
Health Canada: Marketed since 2017-07-31 · brand TARO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Powder for suspension · route Oral · ingredients CLARITHROMYCIN 250 MG/5ML · company Taro pharmaceuticals inc · schedule Prescription
Taro-Clarithromycin: Formulary list price $0.4685/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4685 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87587 · Verify on the e-Formulary ↗ (DIN 02390450)
Source record
DIN 02390450: Taro-Clarithromycin
Raw flags: sec3=Y
Item: 081212031; group id 21; item number 0034; lccId None; manufacturer id TAR
Source form: Susp; strength: 250mg/5mL
Recorded listing: General benefit
Source prices (unrounded): $0.4685; ministry $0.4685
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02390450
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87587Interchangeable products
Biaxin · DIN 02244641 · $0.4685
Shortage status: resolved shortage (ended 2025-01-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02390450
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Clarithromycin · DIN 02274744 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Clarithromycin · DIN 02274744
Manufacturer: Apotex Inc.; listing date 2007-09-04
Daily cost (source): $0.8244
Health Canada: Marketed since 2007-07-26 · brand APO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Apotex inc · schedule Prescription
Apo-Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76021 · Verify on the e-Formulary ↗ (DIN 02274744)
Source record
DIN 02274744: Apo-Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id APX
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02274744
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76021Interchangeable products
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2024-04-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02274744
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biaxin BID · DIN 01984853 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Biaxin BID (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Biaxin BID · DIN 01984853
Manufacturer: BGP Pharma ULC; listing date 1996-10-01
Daily cost (source): $3.9314
Health Canada: Marketed since 2016-08-30 · brand BIAXIN BID · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12779 · Verify on the e-Formulary ↗ (DIN 01984853)
Source record
DIN 01984853: Biaxin BID
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id BGP
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $1.9657; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01984853
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12779Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01984853
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarithromycin · DIN 02442469 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clarithromycin · DIN 02442469
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Daily cost (source): $0.8244
Health Canada: Marketed since 2015-07-22 · brand CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92681 · Verify on the e-Formulary ↗ (DIN 02442469)
Source record
DIN 02442469: Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id SIV
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442469
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92681Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2025-05-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442469
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarithromycin · DIN 02466120 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clarithromycin · DIN 02466120
Manufacturer: Sanis Health Inc.; listing date 2020-04-30
Daily cost (source): $0.8244
Health Canada: Marketed since 2021-07-28 · brand CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Sanis health inc · schedule Prescription
Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95443 · Verify on the e-Formulary ↗ (DIN 02466120)
Source record
DIN 02466120: Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id SAI
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466120
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95443Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2025-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466120
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Clarithromycin · DIN 02361426 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Clarithromycin · DIN 02361426
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-08-04
Daily cost (source): $0.8244
Health Canada: Marketed since 2024-05-28 · brand TARO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Sun pharma canada inc · schedule Prescription
Ran-Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84648 · Verify on the e-Formulary ↗ (DIN 02361426)
Source record
DIN 02361426: Ran-Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id RAN
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361426
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84648Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2020-05-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361426
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Clarithromycin · DIN 02266539 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Clarithromycin · DIN 02266539
Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28
Daily cost (source): $0.8244
Health Canada: Marketed since 2008-06-06 · brand SANDOZ CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75196 · Verify on the e-Formulary ↗ (DIN 02266539)
Source record
DIN 02266539: Sandoz Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id SDZ
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266539
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75196Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2025-04-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266539
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Clarithromycin XL · DIN 02403196
Manufacturer: Actavis Pharma Company; listing date 2014-12-18
Daily cost (source): $2.5144
Health Canada: Marketed since 2024-10-03 · brand TEVA-CLARITHROMYCIN XL · ATC J01FA09 CLARITHROMYCIN · form Tablet (extended-release) · route Oral · ingredients CLARITHROMYCIN 500 MG · company Teva canada limited · schedule Prescription
Act Clarithromycin XL: Formulary list price $1.2572/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2572 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88801 · Verify on the e-Formulary ↗ (DIN 02403196)
Source record
DIN 02403196: Act Clarithromycin XL
Raw flags: sec3=Y
Item: 081212032; group id 21; item number 0032; lccId None; manufacturer id ACV
Source form: ER Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.2572; ministry $1.2572
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02403196
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88801Interchangeable products
Apo-Clarithromycin XL · DIN 02413345 · $1.2572
Biaxin XL · DIN 02244756 · $1.2572
Shortage status: active shortage (reported 2025-10-29, last updated 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403196
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Clarithromycin XL · DIN 02413345
Manufacturer: Apotex Inc.; listing date 2014-10-29
Daily cost (source): $2.5144
Health Canada: Marketed since 2021-07-15 · brand APO-CLARITHROMYCIN XL · ATC J01FA09 CLARITHROMYCIN · form Tablet (extended-release) · route Oral · ingredients CLARITHROMYCIN 500 MG · company Apotex inc · schedule Prescription
Apo-Clarithromycin XL: Formulary list price $1.2572/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.2572 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89802 · Verify on the e-Formulary ↗ (DIN 02413345)
Source record
DIN 02413345: Apo-Clarithromycin XL
Raw flags: sec3=Y
Item: 081212032; group id 21; item number 0032; lccId None; manufacturer id APX
Source form: ER Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $1.2572; ministry $1.2572
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02413345
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89802Interchangeable products
Act Clarithromycin XL · DIN 02403196 · $1.2572
Biaxin XL · DIN 02244756 · $1.2572
Shortage status: resolved shortage (ended 2021-07-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02413345
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Clarithromycin · DIN 02274752 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Clarithromycin · DIN 02274752
Manufacturer: Apotex Inc.; listing date 2007-10-03
Health Canada: Marketed since 2007-07-26 · brand APO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76022 · Verify on the e-Formulary ↗ (DIN 02274752)
Source record
DIN 02274752: Apo-Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id APX
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02274752
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76022Interchangeable products
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02274752
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Biaxin BID · DIN 02126710 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Biaxin BID (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Biaxin BID · DIN 02126710
Manufacturer: BGP Pharma ULC; listing date 2007-10-03
Health Canada: Marketed since 2016-05-20 · brand BIAXIN BID · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Bgp pharma ulc · schedule Prescription
Biaxin BID: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17240 · Verify on the e-Formulary ↗ (DIN 02126710)
Source record
DIN 02126710: Biaxin BID
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id BGP
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02126710
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17240Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2024-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02126710
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarithromycin · DIN 02442485 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clarithromycin · DIN 02442485
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Health Canada: Marketed since 2015-07-22 · brand CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92683 · Verify on the e-Formulary ↗ (DIN 02442485)
Source record
DIN 02442485: Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id SIV
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02442485
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92683Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2025-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02442485
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Clarithromycin · DIN 02466139 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Clarithromycin · DIN 02466139
Manufacturer: Sanis Health Inc.; listing date 2021-05-31
Health Canada: Marketed since 2021-07-28 · brand CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Sanis health inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95444 · Verify on the e-Formulary ↗ (DIN 02466139)
Source record
DIN 02466139: Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02466139
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95444Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2025-05-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466139
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Clarithromycin · DIN 02471396 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
M-Clarithromycin · DIN 02471396
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Health Canada: Marketed since 2018-03-07 · brand M-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Mantra pharma inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96050 · Verify on the e-Formulary ↗ (DIN 02471396)
Source record
DIN 02471396: M-Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id MAT
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471396
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96050Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2020-11-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471396
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Clarithromycin · DIN 02361434 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Clarithromycin · DIN 02361434
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2011-08-04
Health Canada: Marketed since 2024-03-22 · brand TARO-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Sun pharma canada inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84649 · Verify on the e-Formulary ↗ (DIN 02361434)
Source record
DIN 02361434: Ran-Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id RAN
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02361434
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84649Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2025-09-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02361434
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Clarithromycin · DIN 02266547 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Clarithromycin · DIN 02266547
Manufacturer: Sandoz Canada Inc.; listing date 2008-08-28
Health Canada: Marketed since 2008-06-06 · brand SANDOZ CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Sandoz canada incorporated · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75197 · Verify on the e-Formulary ↗ (DIN 02266547)
Source record
DIN 02266547: Sandoz Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266547
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75197Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
PMS-Clarithromycin · DIN 02247574 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: resolved shortage (ended 2025-04-14); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02266547
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Clarithromycin · DIN 02247573 · 250mg · tablet
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Clarithromycin · DIN 02247573
Manufacturer: Pharmascience Inc.; listing date 2007-10-03
Daily cost (source): $0.8244
Health Canada: Dormant since 2024-07-31 · brand PMS-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Pharmascience inc · schedule Prescription
PMS-Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71828 · Verify on the e-Formulary ↗ (DIN 02247573)
Source record
DIN 02247573: PMS-Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id PMS
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247573
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71828Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: discontinued (2023-05-10, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247573
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
PMS-Clarithromycin · DIN 02247574 · 500mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since 2024-07-31 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Clarithromycin · DIN 02247574
Manufacturer: Pharmascience Inc.; listing date 2007-10-03
Health Canada: Dormant since 2024-07-31 · brand PMS-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 500 MG · company Pharmascience inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71829 · Verify on the e-Formulary ↗ (DIN 02247574)
Source record
DIN 02247574: PMS-Clarithromycin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 081212024; group id 21; item number 0036; lccId None; manufacturer id PMS
Source form: Tab; strength: 500mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $2.2009; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247574
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71829Interchangeable products
Apo-Clarithromycin · DIN 02274752 · not recorded
Biaxin BID · DIN 02126710 · not recorded
Clarithromycin · DIN 02442485 · not recorded
Clarithromycin · DIN 02466139 · not recorded
M-Clarithromycin · DIN 02471396 · not recorded
Ran-Clarithromycin · DIN 02361434 · not recorded
Sandoz Clarithromycin · DIN 02266547 · not recorded
Teva-Clarithromycin · DIN 02248805 · not recorded
Shortage status: discontinued (2023-05-10, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247574
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
M-Clarithromycin · DIN 02471388 · 250mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-13 — choose a marketed DIN from the same-category list.Discontinued 2023-07-13 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-13 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-07-13 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Clarithromycin · DIN 02471388
Manufacturer: Mantra Pharma Inc.; listing date 2021-10-29
Daily cost (source): $0.8244
Health Canada: Cancelled post market since 2023-07-13 · brand M-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Mantra pharma inc · schedule Prescription
M-Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96049 · Verify on the e-Formulary ↗ (DIN 02471388)
Source record
DIN 02471388: M-Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id MAT
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02471388
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96049Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Teva-Clarithromycin · DIN 02248804 · $0.4122
Shortage status: resolved shortage (ended 2020-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02471388
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-07-13 — choose a marketed DIN from the same-category list.
Teva-Clarithromycin · DIN 02248804 · 250mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-05-28 — choose a marketed DIN from the same-category list.Discontinued 2021-05-28 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-05-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-05-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Clarithromycin · DIN 02248804
Manufacturer: Teva Canada Limited; listing date 2012-12-21
Daily cost (source): $0.8244
Health Canada: Cancelled post market since 2021-05-28 · brand TEVA-CLARITHROMYCIN · ATC J01FA09 CLARITHROMYCIN · form Tablet · route Oral · ingredients CLARITHROMYCIN 250 MG · company Teva canada limited · schedule Prescription
Teva-Clarithromycin: Formulary list price $0.4122/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4122 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73173 · Verify on the e-Formulary ↗ (DIN 02248804)
Source record
DIN 02248804: Teva-Clarithromycin
Raw flags: sec3=Y
Item: 081212020; group id 21; item number 0035; lccId None; manufacturer id TEV
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4122; ministry $0.4122
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248804
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73173Interchangeable products
Apo-Clarithromycin · DIN 02274744 · $0.4122
Biaxin BID · DIN 01984853 · $0.4122
Clarithromycin · DIN 02442469 · $0.4122
Clarithromycin · DIN 02466120 · $0.4122
M-Clarithromycin · DIN 02471388 · $0.4122
PMS-Clarithromycin · DIN 02247573 · $0.4122
Ran-Clarithromycin · DIN 02361426 · $0.4122
Sandoz Clarithromycin · DIN 02266539 · $0.4122
Shortage status: discontinued (2020-06-08, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248804
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-05-28 — choose a marketed DIN from the same-category list.
General benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.Discontinued 2020-09-16 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Biaxin XL · DIN 02244756
Manufacturer: BGP Pharma ULC; listing date 2003-01-30
Daily cost (source): $5.1344
Health Canada: Cancelled post market since 2020-09-16 · brand BIAXIN XL · ATC J01FA09 CLARITHROMYCIN · form Tablet (extended-release) · route Oral · ingredients CLARITHROMYCIN 500 MG · company Bgp pharma ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68745 · Verify on the e-Formulary ↗ (DIN 02244756)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02244756).
DIN 02244756: Biaxin XL
Raw flags: dinStatus=E, sec3=Y
Item: 081212032; group id 21; item number 0032; lccId None; manufacturer id BGP
Source form: ER Tab; strength: 500mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $2.5672; ministry $1.2572
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02244756
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=68745Interchangeable products
Act Clarithromycin XL · DIN 02403196 · $1.2572
Apo-Clarithromycin XL · DIN 02413345 · $1.2572
Shortage status: active shortage (reported 2016-12-08, last updated 2020-07-24) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244756
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-09-16 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:12:12 Erythromycins) and how they are covered
Matched class: 08:12:12 Erythromycins
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): AZITHROMYCIN, ERYTHROMYCIN BASE, ERYTHROMYCIN ESTOLATE, ERYTHROMYCIN ETHYLSUCCINATE
08:12:12 Erythromycins
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered
Matched class: 56:40 Miscellaneous G.I. Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE
Some products covered without a code (check the product listing): 5-AMINOSALICYLIC ACID, CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL
56:40 Miscellaneous G.I. Drugs
· 6 products · General benefit · strengths: 40mg · Ent Coated Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40
and 10 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
CIPROFLOXACIN AND DEXAMETHASONE · Limited Use, codes 509
INDICATIONS AND CLINICAL USE
CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of
infections caused by most strains of the designated microorganisms in the specific conditions
listed below:
Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6
months of age due to:
Aerobic, Gram-Positive:
Streptococcus pneumoniae
Staphylococcus aureus
Aerobic, Gram-Negative:
Haemophilus influenza
Moraxella catarrhalis
Pseudomonas aeruginosa
Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to:
Aerobic, Gram-Positive:
Staphylococcus aureus
Aerobic, Gram-Negative:
Pseudomonas aeruginosa
To reduce the development of drug-resistant bacteria and maintain the effectiveness of
CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections
that are proven or strongly suspected to be caused by susceptible bacteria.
PM: https://pdf.hres.ca/dpd_pm/00041611.PDF; date September 27, 2017; DIN 02252716; fetched 2026-09-10
Product monographTETRACYCLINE · Listed, not a benefit (1), General benefit (1)
Indications
TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following
microorganisms:
• Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever,
rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis,
agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis).
PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
BIAXIN BID® (clarithromycin tablets USP, film-coated)
BIAXIN BID® may be indicated in the treatment of mild to moderate infections caused by susceptible
strains of the designated microorganisms in the diseases listed below:
• Upper Respiratory Tract
• Pharyngiitis/tonsillitis, caused by Streptococcus pyogenes (Group A beta-hemolytic
streptococci).
• Acute maxillary sinusitis caused by Streptococcus pneumoniae (S. pneumoniae), Haemophilus
influenzae (H. influenzae), and Moraxella (Branhamella) catarrhalis [M. (Branhamella)
catarrhalis].
• Lower Respiratory Tract
• Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae, H. influenzae
(including beta-lactamase producing strains), M. (Branhamella) catarrhalis (including beta-
lactamase producing strains).
• Pneumonia caused by S. pneumoniae and Mycoplasma. pneumoniae (M. pneumoniae). See
WARNINGS AND PRECAUTIONS, Susceptibility/Resistance.
• Uncomplicated Skin and Skin Structure Infections
• Uncomplicated Skin and Skin Structure Infections caused by Streptococcus pyogenes (S.
pyogenes), Staphylococcus aureus…
https://pdf.hres.ca/dpd_pm/00078094.PDF
PM date: DEC 17, 2024
Source product: BIAXIN BID; DIN 01984853; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
The components of the AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN [lansoprazole
delayed-release capsules, in combination with clarithromycin tablets plus amoxicillin capsules
as triple therapy], are indicated for:
● the treatment of patients with Helicobacter pylori (H. pylori) infection and active
duodenal ulcer disease. Eradication of H. pylori has been shown to reduce the risk of
duodenal ulcer recurrence (see 14.1 Clinical Trials by Indication and 4 DOSAGE AND
ADMINISTRATION).
In patients with a recent history of duodenal ulcers who are H. pylori positive, eradication
therapy may reduce the rate of recurrence of duodenal ulcers. The optimal timing for
eradication therapy for such patients remains to be determined.
In patients who fail a therapy combination containing clarithromycin, susceptibility testing
should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not
possible, an alternative therapy combination is recommended. Resistance to amoxicillin has not
been demonstrated in clinical studies with lansoprazole delayed-release capsules and
amoxicillin.
Table 1 summarizes the eradication rates for th…
https://pdf.hres.ca/dpd_pm/00077480.PDF
PM date: OCT 18, 2024
Source product: AA-LANSOPRAZOLE-AMOXICILLIN-CLARITHROMYCIN; DIN 02470780; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Act Clarithromycin XL · DIN 02403196
Shortage status: active shortage (reported 2025-10-29, last updated 2025-10-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02403196
Biaxin XL · DIN 02244756
Shortage status: active shortage (reported 2016-12-08, last updated 2020-07-24) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02244756
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)
Other review policies
For Apo-Clarithromycin, Biaxin BID, Clarithromycin, M-Clarithromycin, Ran-Clarithromycin, Sandoz Clarithromycin, PMS-Clarithromycin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.